Padierna-Luna JL, Ochoa-Rosas FS, Jaramillo-Villalobos B

Language: Spanish
References: 27
Page: 593-599
PDF size: 141.01 Kb.

ABSTRACT

Objective: to determine the prevalence of metabolic syndrome in health employees of a general hospital in Celaya, Guanajuato.
Methods: design: cross-sectional survey to 200 healthy employees who were selected by labor category: nurses 71 (35%), general services 66 (33%), administrative 39 (19.5%), physicians 12 (6%) and chiefs of clinical department 12 (6%). The instrument was used to detect risk factors, evaluate clinically and through laboratory tests. The diagnosis of metabolic syndrome was done by following the NCEP-ATPIII criteria. A descriptive analysis was carried out.
Results: the study included 142 women (71%) and 58 men (29%) with an average age of 41 years (range 19 to 59). The global prevalence of MS was 29.5% (59 events). Six new cases of type 2 diabetes mellitus (3%), 38 with abnormal fasting glucose (19%) and 33 with abnormal blood pressure (16.5%): 23 participants with pre-hypertension, 7 in stage 1 and 3 in stage 2 were detected. Ten employees with MS (21%) tested positive for C-reactive protein.
Conclusion: the prevalence of MS of health employees is above figures reported in the literature for the general population.

REFERENCES

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.

2. González-Chávez A, Alexánderson EG, Alvarado A, Becerra R, Camacho J, Carmona FK, et al. Consenso mexicano sobre tratamiento integral del síndrome metabólico. Rev Mex Cardiol 2002;13(1):4-30.

3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of WHO consultation. Diabet Med 1998;15:539-553.

4. Reaven GM. Pathophysiology of insulin resistance in human diseases. Physiol Rev 1995;75:473-486.

5. Rewers M, Shetterly SM. Cool. Insulin and cardiovascular disease in Hispanics and non-hispanic whites (NHW): the San Luis Valley Diabetes Study. Circulation 1992;85:865.

6. Ferrara A, Barrett-Connor E, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or woman without diabetes: the Rancho Bernardo Study, 1984 to 1991. Am J Epidemiol 1994;140: 857-869.

7. Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P. Glucose tolerance and coronary heart disease: Helsinki Policeman Study. J Chronic Dis 1979;32:729-745.

8. Lakka MP, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002;288:2709-2716.

9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. AJP: Endocrinology and Metabolism 1979;237(3):E214-E223

10. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.

11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-359.

12. Velázquez-Monroy O, Rosas PM, Lara E, Pastelín HG, Attie F, Tapia-Conyer R. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72:71-84

13. Aguilar-Salinas C, Rojas R, Gómez-Pérez FJ, Franco A, Olaiz G, Rull JA, et al. El síndrome metabólico: un concepto en evolución. Gac Med Mex 2004;140 (2):S41-48.

14. Ford ES, et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.

15. Luquez H, De Loredo I, Mandoery R, Senestrari D. Síndrome metabólico: prevalencia de dos comunidades de Córdoba, Argentina, de acuerdo con definiciones ATP-III y OMS. Rev Fed Arg Cardillo 2005;43:80-95.

16. Ministerio de Salud de Chile. Encuesta Nacional de Salud. Disponible en http://www.minsaI.gob.cI

17. Stern MP, et al. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerant test? Ann Intern Med 2002;136:575-581.

18. Pearson TA, Mensah GA; R. Alexander W, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinic and public health practice: a statement for healthcare professionals from of Centres for Diseases Central and Prevention and the American Health Association. Circulation 2003;107:499-511.

19. González A, Sánchez M. Inflamación y resistencia a la insulina, su papel en el desarrollo del síndrome metabólico. Annual Review del Colegio de Medicina Interna de México. México: Intersistemas; 2005. p. 177-191.

20. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase protein and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 2002;51:1131-1137.

21. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27: 978-983.

22. Alberti KG, Zimmet S. The metabolic syndrome: a new worldwide definition. Lancet 2005;366: 1059-1062.

23. Howard BV, et al. Rising tide of cardiovascular disease in American Indians: the Strong Heart Study. Circulation 1999;2389-2395.

24. Simmons D, Thompson Colin. Prevalence of the metabolic syndrome among adult New Zealanders of Polynesian and European descent. Diabetes Care 2004;27:3002-3004.

25. Meigs JB, Wilson PW, Nathan DM, D’Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160-2167.

26. Ridker PM, Buring JE, Cook NR, Rifai N. Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:391-397.

27. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29.